Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofersen in SOD1-ALS (Extension Study)
NCT03070119Phase 3Completed
- Sponsor
- Biogen
- Start
- Mar 2017
- Primary completion
- Aug 2024
- Countries
- 9
01
Overview
A Phase 3 trial of tofersen in amyotrophic lateral sclerosis (ALS), sponsored by Biogen. Started Mar 2017; status: completed.
02
Drugs
tofersen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03070119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070119.